Aclaris Therapeutics, Inc. (0H8T.L)
| Previous close | 1.3200 |
| Open | 1.3020 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.3000 - 1.3020 |
| 52-week range | 0.6052 - 10.8700 |
| Volume | |
| Avg. volume | 12,279 |
| Market cap | 380,156 |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3600 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2024 on Tuesday, May 7, 2024, after the closing of the U.S. financial markets. Management will conduct a conference call at 5:00 p.m. ET on the same day to provide a corporate update. The conference call will be webcas
PR NewswireFlare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph
Simply Wall St.Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
